APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Diagnostic Nuclear Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Diagnostic Nuclear Drug Market Outlook and Growth Opportunities 2026

2 January 2026196 pages

Choose your research edition.

Industry ResearchDiagnostic Nuclear Drug Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Diagnostic Nuclear Drug Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Diagnostic Nuclear Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diagnostic Nuclear Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Diagnostic Nuclear Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Diagnostic Nuclear Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Diagnostic Nuclear Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diagnostic Nuclear Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diagnostic Nuclear Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Diagnostic Nuclear Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Diagnostic Nuclear Drug market include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Diagnostic Nuclear Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diagnostic Nuclear Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diagnostic Nuclear Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Diagnostic Nuclear Drug market.

Diagnostic Nuclear Drug Segment by Company

Bracco Imaging

Cardinal Health

Curium Pharma

GE Healthcare

Jubilant Pharma

Lantheus

SIEMENS

Dongcheng

Eli Lilly

Novartis

China Isotope & Radiation

Diagnostic Nuclear Drug Segment by Type

Tc-99m

F-18

Other

Diagnostic Nuclear Drug Segment by Application

Oncology

Cardiology

Other

Diagnostic Nuclear Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Diagnostic Nuclear Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Diagnostic Nuclear Drug key companies, revenue, market share, and recent developments.

3. To split the Diagnostic Nuclear Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Diagnostic Nuclear Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Diagnostic Nuclear Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Diagnostic Nuclear Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diagnostic Nuclear Drug industry.

Chapter 3: Detailed analysis of Diagnostic Nuclear Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Diagnostic Nuclear Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Diagnostic Nuclear Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Diagnostic Nuclear Drug Industry Trends Table 2. Diagnostic Nuclear Drug Industry Drivers Table 3. Diagnostic Nuclear Drug Industry Opportunities and Challenges Table 4. Diagnostic Nuclear Drug Industry Restraints Table 5. Global Diagnostic Nuclear Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Diagnostic Nuclear Drug Revenue Share by Company (2021-2026) Table 7. Global Diagnostic Nuclear Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Diagnostic Nuclear Drug Key Company Manufacturing Base & Headquarters Table 9. Global Diagnostic Nuclear Drug Company, Product Type & Application Table 10. Global Diagnostic Nuclear Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Diagnostic Nuclear Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tc-99m Table 15. Significant Companies of F-18 Table 16. Significant Companies of Other Table 17. Global Diagnostic Nuclear Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Diagnostic Nuclear Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Diagnostic Nuclear Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Diagnostic Nuclear Drug Sales Value Share by Type (2021-2026) Table 21. Global Diagnostic Nuclear Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Oncology Table 23. Significant Companies of Cardiology Table 24. Significant Companies of Other Table 25. Global Diagnostic Nuclear Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Diagnostic Nuclear Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Diagnostic Nuclear Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Diagnostic Nuclear Drug Sales Value Share by Application (2021-2026) Table 29. Global Diagnostic Nuclear Drug Sales Value Share by Application (2027-2032) Table 30. Global Diagnostic Nuclear Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Diagnostic Nuclear Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Diagnostic Nuclear Drug Sales Value Share by Region (2021-2026) Table 33. Global Diagnostic Nuclear Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Diagnostic Nuclear Drug Sales Value Share by Region (2027-2032) Table 35. Global Diagnostic Nuclear Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Diagnostic Nuclear Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Diagnostic Nuclear Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Diagnostic Nuclear Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Diagnostic Nuclear Drug Sales Value Market Share by Country (2027-2032) Table 40. Bracco Imaging Company Information Table 41. Bracco Imaging Business Overview Table 42. Bracco Imaging Diagnostic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Bracco Imaging Diagnostic Nuclear Drug Product Portfolio Table 44. Bracco Imaging Recent Development Table 45. Cardinal Health Company Information Table 46. Cardinal Health Business Overview Table 47. Cardinal Health Diagnostic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Cardinal Health Diagnostic Nuclear Drug Product Portfolio Table 49. Cardinal Health Recent Development Table 50. Curium Pharma Company Information Table 51. Curium Pharma Business Overview Table 52. Curium Pharma Diagnostic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Curium Pharma Diagnostic Nuclear Drug Product Portfolio Table 54. Curium Pharma Recent Development Table 55. GE Healthcare Company Information Table 56. GE Healthcare Business Overview Table 57. GE Healthcare Diagnostic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. GE Healthcare Diagnostic Nuclear Drug Product Portfolio Table 59. GE Healthcare Recent Development Table 60. Jubilant Pharma Company Information Table 61. Jubilant Pharma Business Overview Table 62. Jubilant Pharma Diagnostic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Jubilant Pharma Diagnostic Nuclear Drug Product Portfolio Table 64. Jubilant Pharma Recent Development Table 65. Lantheus Company Information Table 66. Lantheus Business Overview Table 67. Lantheus Diagnostic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Lantheus Diagnostic Nuclear Drug Product Portfolio Table 69. Lantheus Recent Development Table 70. SIEMENS Company Information Table 71. SIEMENS Business Overview Table 72. SIEMENS Diagnostic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. SIEMENS Diagnostic Nuclear Drug Product Portfolio Table 74. SIEMENS Recent Development Table 75. Dongcheng Company Information Table 76. Dongcheng Business Overview Table 77. Dongcheng Diagnostic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Dongcheng Diagnostic Nuclear Drug Product Portfolio Table 79. Dongcheng Recent Development Table 80. Eli Lilly Company Information Table 81. Eli Lilly Business Overview Table 82. Eli Lilly Diagnostic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Eli Lilly Diagnostic Nuclear Drug Product Portfolio Table 84. Eli Lilly Recent Development Table 85. Novartis Company Information Table 86. Novartis Business Overview Table 87. Novartis Diagnostic Nuclear Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Novartis Diagnostic Nuclear Drug Product Portfolio Table 89. Novartis Recent Development Table 90. China Isotope & Radiation Company Information Table 91. China Isotope & Radiation Business Overview Table 92. China Isotope & Radiation Diagnostic Nuclear Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. China Isotope & Radiation Diagnostic Nuclear Drug Product Portfolio Table 94. China Isotope & Radiation Recent Development Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Diagnostic Nuclear Drug Product Image Figure 2. Global Diagnostic Nuclear Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diagnostic Nuclear Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Diagnostic Nuclear Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tc-99m Image Figure 8. F-18 Image Figure 9. Other Image Figure 10. Global Diagnostic Nuclear Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Diagnostic Nuclear Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Diagnostic Nuclear Drug Sales Value Share by Type (2021-2032) Figure 13. Oncology Image Figure 14. Cardiology Image Figure 15. Other Image Figure 16. Global Diagnostic Nuclear Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Diagnostic Nuclear Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Diagnostic Nuclear Drug Sales Value Share by Application (2021-2032) Figure 19. Global Diagnostic Nuclear Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Diagnostic Nuclear Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Diagnostic Nuclear Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Diagnostic Nuclear Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Diagnostic Nuclear Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Diagnostic Nuclear Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Diagnostic Nuclear Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Diagnostic Nuclear Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Diagnostic Nuclear Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Diagnostic Nuclear Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Diagnostic Nuclear Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Diagnostic Nuclear Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Tc-99m
  • F-18
  • Other
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Bracco Imaging
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus
  • SIEMENS
  • Dongcheng
  • Eli Lilly
  • Novartis
  • China Isotope & Radiation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Diagnostic Nuclear Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Diagnostic Nuclear Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Diagnostic Nuclear Drug Market Dynamics
  1. 2.1 Diagnostic Nuclear Drug Industry Trends
  2. 2.2 Diagnostic Nuclear Drug Industry Drivers
  3. 2.3 Diagnostic Nuclear Drug Industry Opportunities and Challenges
  4. 2.4 Diagnostic Nuclear Drug Industry Restraints
3 Diagnostic Nuclear Drug Market by Company
  1. 3.1 Global Diagnostic Nuclear Drug Company Revenue Ranking in 2025
  2. 3.2 Global Diagnostic Nuclear Drug Revenue by Company (2021-2026)
  3. 3.3 Global Diagnostic Nuclear Drug Company Ranking (2024-2026)
  4. 3.4 Global Diagnostic Nuclear Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Diagnostic Nuclear Drug Company Product Type and Application
  6. 3.6 Global Diagnostic Nuclear Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Diagnostic Nuclear Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Diagnostic Nuclear Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Diagnostic Nuclear Drug Market by Type
  1. 4.1 Diagnostic Nuclear Drug Type Introduction
  2. 4.1.1 Tc-99m
  3. 4.1.2 F-18
  4. 4.1.3 Other
  5. 4.2 Global Diagnostic Nuclear Drug Sales Value by Type
  6. 4.2.1 Global Diagnostic Nuclear Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Diagnostic Nuclear Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Diagnostic Nuclear Drug Sales Value Share by Type (2021-2032)
5 Diagnostic Nuclear Drug Market by Application
  1. 5.1 Diagnostic Nuclear Drug Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Cardiology
  4. 5.1.3 Other
  5. 5.2 Global Diagnostic Nuclear Drug Sales Value by Application
  6. 5.2.1 Global Diagnostic Nuclear Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Diagnostic Nuclear Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Diagnostic Nuclear Drug Sales Value Share by Application (2021-2032)
6 Diagnostic Nuclear Drug Regional Value Analysis
  1. 6.1 Global Diagnostic Nuclear Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diagnostic Nuclear Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Diagnostic Nuclear Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Diagnostic Nuclear Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Diagnostic Nuclear Drug Sales Value (2021-2032)
  7. 6.3.2 North America Diagnostic Nuclear Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Diagnostic Nuclear Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Diagnostic Nuclear Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Diagnostic Nuclear Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Diagnostic Nuclear Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Diagnostic Nuclear Drug Sales Value (2021-2032)
  16. 6.6.2 South America Diagnostic Nuclear Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Diagnostic Nuclear Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Diagnostic Nuclear Drug Sales Value Share by Country, 2025 VS 2032
7 Diagnostic Nuclear Drug Country-level Value Analysis
  1. 7.1 Global Diagnostic Nuclear Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Diagnostic Nuclear Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Diagnostic Nuclear Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Diagnostic Nuclear Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Diagnostic Nuclear Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Diagnostic Nuclear Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Diagnostic Nuclear Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bracco Imaging
  2. 8.1.1 Bracco Imaging Company Information
  3. 8.1.2 Bracco Imaging Business Overview
  4. 8.1.3 Bracco Imaging Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bracco Imaging Diagnostic Nuclear Drug Product Portfolio
  6. 8.1.5 Bracco Imaging Recent Developments
  7. 8.2 Cardinal Health
  8. 8.2.1 Cardinal Health Company Information
  9. 8.2.2 Cardinal Health Business Overview
  10. 8.2.3 Cardinal Health Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Cardinal Health Diagnostic Nuclear Drug Product Portfolio
  12. 8.2.5 Cardinal Health Recent Developments
  13. 8.3 Curium Pharma
  14. 8.3.1 Curium Pharma Company Information
  15. 8.3.2 Curium Pharma Business Overview
  16. 8.3.3 Curium Pharma Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Curium Pharma Diagnostic Nuclear Drug Product Portfolio
  18. 8.3.5 Curium Pharma Recent Developments
  19. 8.4 GE Healthcare
  20. 8.4.1 GE Healthcare Company Information
  21. 8.4.2 GE Healthcare Business Overview
  22. 8.4.3 GE Healthcare Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GE Healthcare Diagnostic Nuclear Drug Product Portfolio
  24. 8.4.5 GE Healthcare Recent Developments
  25. 8.5 Jubilant Pharma
  26. 8.5.1 Jubilant Pharma Company Information
  27. 8.5.2 Jubilant Pharma Business Overview
  28. 8.5.3 Jubilant Pharma Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Jubilant Pharma Diagnostic Nuclear Drug Product Portfolio
  30. 8.5.5 Jubilant Pharma Recent Developments
  31. 8.6 Lantheus
  32. 8.6.1 Lantheus Company Information
  33. 8.6.2 Lantheus Business Overview
  34. 8.6.3 Lantheus Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Lantheus Diagnostic Nuclear Drug Product Portfolio
  36. 8.6.5 Lantheus Recent Developments
  37. 8.7 SIEMENS
  38. 8.7.1 SIEMENS Company Information
  39. 8.7.2 SIEMENS Business Overview
  40. 8.7.3 SIEMENS Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 SIEMENS Diagnostic Nuclear Drug Product Portfolio
  42. 8.7.5 SIEMENS Recent Developments
  43. 8.8 Dongcheng
  44. 8.8.1 Dongcheng Company Information
  45. 8.8.2 Dongcheng Business Overview
  46. 8.8.3 Dongcheng Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Dongcheng Diagnostic Nuclear Drug Product Portfolio
  48. 8.8.5 Dongcheng Recent Developments
  49. 8.9 Eli Lilly
  50. 8.9.1 Eli Lilly Company Information
  51. 8.9.2 Eli Lilly Business Overview
  52. 8.9.3 Eli Lilly Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly Diagnostic Nuclear Drug Product Portfolio
  54. 8.9.5 Eli Lilly Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Diagnostic Nuclear Drug Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 China Isotope & Radiation
  62. 8.11.1 China Isotope & Radiation Company Information
  63. 8.11.2 China Isotope & Radiation Business Overview
  64. 8.11.3 China Isotope & Radiation Diagnostic Nuclear Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 China Isotope & Radiation Diagnostic Nuclear Drug Product Portfolio
  66. 8.11.5 China Isotope & Radiation Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst